MELIVEN

MELIVEN PLUS 20 CAPSULES

MELIVEN PLUS 20 CAPSULES

Skip to product information
1 of 2
  • Secure payment
  • Discreet and sanitized package
  • Fast and safe shipping

Description

Descriptive sheet

MELIVEN PLUS

Description
Food supplement containing rutin and sweet clover extract.
Melilot is useful for the functionality of the microcirculation and for venous circulation.

Ingredients
Rutin, edible gelatine, sweet clover (Melilotus officinalis Pallas) dry herb extract with flowers at 17%-20% in coumarin.

Gluten free.

How to use
1 capsule per day to be swallowed with water.

Warnings
Do not exceed the recommended daily dose. Keep out of reach of children under 3 years of age. Food supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle.

Format
20 capsule

MELIVEN

MELIVEN PLUS 20 CAPSULES

MELIVEN PLUS 20 CAPSULES

MINSAN code: 900095769
Previous price: €21,84
Regular price €21,84
Regular price €0,00 Sale price €21,84
-% Sold out
Tax included. Shipping calculated at checkout.
View full details

Product images are purely indicative and may not be fully representative of the packaging and product features, as they may vary in color, size, or content. Any decorations, gift wrapping, and items included in the images for product presentation purposes will not be shipped with orders. Product names, ingredients, and percentages indicated in the descriptions are purely indicative and may be subject to change or updates by the manufacturers. Due to the impossibility of updating these updates in real time, the photos and technical information of the products listed on farmaInnovation.it may differ from those shown on the label or otherwise disclosed by the manufacturers. The only identifying element is the MINSAN (Ministry of Health) code. Farmacia Barni, farmainnovation.it , does not guarantee the accuracy and timeliness of the information published and declines all responsibility for any errors, omissions, or failure to update it. farmainnovation.it assumes no responsibility for damages of any kind that may arise from accessing the published information.